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Abbreviation  Full Term  
ALL acute lymphoblastic leukemia  
MRD minimal residual disease  
FISH fluorescence in situ hybridization 
CML chronic myelogenous leukemia  
RT reverse transcription  
PCR polymerase chain reaction  
TCR T-cell receptor  
FACS fluorescent-activated cell sorter  
  
HSCT hematopoietic stem cell transplant 
BP blast phase  
PB peripheral blood 
BM bone marrow  
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Abstract 
BCR-ABL1-positive leukemias have historically been classified as either CML or Ph+ acute 
lymphoblastic leukemia. Recent analyses suggest there may be a wider range of subtypes.  We 
report a patient with BCR-ABL1 fusion positive T-ALL with a previously undescribed cell 
distribution of the fusion gene. The examination of sorted cells by fluorescence in situ 
hybridization (FISH) showed the BCR-ABL1 fusion in the malignant T-cells and a 
subpopulation of the non-malignant B-cells, but not non-malignant T-cells, myeloid or CD34+ 
progenitor cells providing evidence that the fusion may have occurred in an early lymphoid 
progenitor.  
Introduction  
The BCR-ABL1 fusion gene is the hallmark of chronic myelogenous leukemia (CML) and is 
also present in a subtype of ALL. Hovorkova et. al1 provided evidence that patients presenting 
with BCR-ABL1 fusion-positive ALL might represent a spectrum of leukemia subtypes. They 
demonstrated that minimal residual disease (MRD) measured by the BCR-ABL1 fusion gene 
polymerase chain reaction (PCR) and the immunoglobulin gene /T-cell receptor (TCR) gene 
PCR was concordant in the majority of cases and that the fusion gene was confined to the 
lymphoid blasts. However, in about 20% of the cases the MRD was discordant and the fusion 
gene was present not only in the malignant blasts but also in non-malignant cells suggesting that 
the fusion might have occurred in a multipotent progenitor cell. The BCR-ABL1 fusion gene is 
almost always found in malignant B-cells and has been reported only rarely in malignant T-cells. 
2-4 We describe a patient with BCR-ABL1 transcripts in the malignant T-cells and in a 
subpopulation of non-malignant B cells. Progenitor cells, myeloid cells, non-malignant T-cells 
and a population of normal B-cells were BCR-ABL1 negative.  The TCR beta and gamma genes 
4 
 
were not rearranged in the malignant T-cells. These combined results suggest that the BCR-
ABL1 fusion may have occurred in an early lymphoid progenitor. Determining the cell type of 
origin is important, as each cell type may have distinct biological properties and may require 
different treatment.5-7 Including FISH analysis for BCR/ABL1 fusions in fluorescent-activated 
cell sorter (FACS)-sorted cells and genomic analysis during induction may lead to a better 
understanding of the frequency and outcome of the different BCR-ABL1-positive leukemia 
subtypes.  
 
Case description and methods 
A 13-year-old male presented with a white blood cell count of 426 x 109/L, hemoglobin 11.5 
g/dl, and platelets 115 109/L. The review of the peripheral blood (PB) smear showed 84% blasts, 
1% myelocytes, 1% metamyelocytes, 1% bands, 3% neutrophils, 12% lymphocytes, and 1% 
monocytes. His creatinine was 0.6 and uric acid 7.7. A computed tomography scan was 
remarkable for splenomegaly and enlarged abdominal lymph nodes; there was no mediastinal 
mass. Blasts comprised 77% of the marrow cellularity and were positive for CD34 (minimal), 
CD7, CD5, CD4, CD8 (partial), CD1a (partial), CD38, cytoplasmic CD3, and TdT but negative 
for B-cell and myeloid markers. The cerebrospinal fluid was negative. FISH was positive for the 
BCR-ABL1 fusion gene. The ABL kinase domain mutation analysis of his BCR-ABL1 fusion 
protein (p190) was negative. Cytogenetic studies revealed no other abnormalities. He was started 
on four-drug induction and the tyrosine kinase inhibitor, dasatinib. His initial clinical course was 
complicated by tumor lysis syndrome and acute kidney injury requiring continuous venovenous 
hemodiafiltration. 
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On induction day 8, 3.5% T-lymphoblasts were detected in the PB by flow cytometry but the 
quantitative BCR-ABL1 reverse transcription (RT) PCR was positive at 42.51% (ratio of fusion  
gene transcript /ABL1 reference gene transcript multiplied by 100)   in the nucleated cells. Due 
to this discrepancy we performed FACS followed by BCR-ABL1 FISH analysis to determine 
which cell populations were positive for the BCR-ABL1 fusion. His PB (day 15) and bone 
marrow (BM) cells (day 29) were sorted into CD5+CD3- malignant T-cells, CD3+ non-
malignant T-cells, CD33+ non-malignant neutrophils, CD19+ non-malignant B-cells, and 
CD34+ non-malignant progenitor cells at Hematologics Inc. FISH was performed on the sorted 
cells with the BCR-ABL1 + ASS1 (9q34) tricolor dual fusion translocation probe, A total of 
200-300 sorted interphase nuclei were examined for each cell type. Multiplex PCR with specific 
primers for the TCR beta and gamma chain was performed on sorted and unsorted PB (day 15).  
His BM at diagnosis was further characterized with targeted sequencing studies with the 
FoundationOne Heme panel.  After completing induction therapy, he was treated with four 
cycles of Hyper-CVAD with ponatinib.8 His MRD testing by RT-PCR were consistently higher 
in the PB compared to his BM prior to his HSCT, likely due to the lower number of lymphocytes 
in the BM compared to PB. 9-12 (Table 1) After recovery from his fourth cycle of chemotherapy, 
he received a matched-related allogeneic hematopoietic stem cell transplant (HSCT). His post-
transplant BM MRD by flow cytometry has remained negative (Table 1). 
 
Results 
The FISH analysis of the CD5+CD3- malignant T-cell fraction revealed an abnormal dual fusion 
signal pattern (1R1G2F2A) indicative of a t(9;22) BCR-ABL1 gene rearrangement in 86% of the 
PB cells and 80% of the BM cells examined (Fig. 1B). In addition, the CD19+ non-malignant B-
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cell fraction revealed an abnormal dual fusion signal pattern (1R1G2F2A) in 22% of the PB cells 
and 14% of the BM cells, suggestive of a BCR-ABL1 gene rearrangement in a sub-clone of the 
non-malignant B-cell compartment (Fig. 1D). Analysis of the non-malignant CD33+ neutrophil 
and CD3+ T-cell fractions were negative for the BCR-ABL1 gene rearrangement (Figs 1A and 
1C).  TCR beta and gamma chain multiplex PCR did not reveal presence of clonal amplification 
in the malignant T-cell fraction and the non-malignant B-cell fraction. The targeted sequencing 
studies revealed a mutation of FBXW7 pR465C (mutation allelic frequency (MAF) 9%) and 
CDKN2A 16INK4a pW110* and CDKN2A 14ARF pG125R (MAF 78%). IKFZ1 was not 
mutated or deleted. The number of mutations was intermediate at 7 mutations/Mb. 
 
Discussion  
The BCR-ABL1 fusion in acute leukemia with T-cell differentiation usually leads to the 
differential diagnosis of either CML with T-cell blast phase (BP) or de novo BCR-ABL1-
positive T-ALL. The incidence of each is rare. Only 1.3% of CML-BP have a T-lymphoid BP 
and less than 5% of BCR-ABL1 fusion-positive ALL are T- ALL.2,3 Distinguishing CML-BP 
from de novo ALL can be very challenging, especially if there is no prior history of CML, 
although the lack of TCR beta and gamma rearrangement would favor a leukemia arising in an 
early progenitor cell.3 Hovorkova1 et. al provide data suggesting even greater complexity with a 
spectrum of BCR-ABL1 fusion-positive B-cell leukemias. In 20% of the cases the BCR-ABL1 
fusion was present to variable degrees in the non-malignant B and T-lymphoid cells and 
granulocytes. Patients with CML had BCR-ABL1 positive monocytes and granulocytes but not T 
cells. In their small study, the 15 ALL patients with multilineage involvement had a better 
outcome with HSCT than with chemotherapy alone.   
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BCR-ABL1-positive ALL and lymphoid blastic transformation of CML very rarely involve the 
T-cell lineage. The reason for the myeloid and B-cell predominance is not known. Genome-wide 
analysis have shown that IKFZ1 deletions occur in CML during progression to lymphoid BP in 
B-lymphoid blasts (84%) but rarely in T-cell blasts.13 CDKN2A/B deletions occur in both B and 
T-cell BCR-ABL1-positive lymphoid blasts during progression of CML to lymphoid BP.14 Both 
genomic alteration, the CDKN2A/B deletions and the lack of an IKFZ1 deletion, and the cell of 
origin may be related to our patient’s T-cell phenotype.  
 
Much more work is needed to understand the underlying genetic lesions and the clinical 
implications of multilineage involvement in BCR-ABL1-positive disease, especially as it relates 
to T-ALL. FISH analysis of cells sorted into lineage specific populations and genomic analysis 
are feasible and can be included into routine diagnostic procedures and will undoubtedly lead to 
a better characterization of these BCR-ABL1-positive leukemic subtypes.  Although the optimal 
therapy for subtypes with multilineage involvement has yet to be defined, we believe the current 
standard practice is HCST analogous to CML that presents in BP. 15 
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TABLE 1 RT-PCR and MRD results during treatment 
Timepoint  BCR-ABL % residual disease RT-PCR MRD % by flow cytometry 
  PB BM PB BM 
Induction day 8 42.5   3.5   
Induction day 29 19.5 6.8   4.3 
Hyper-CVAD Cycle 2 0.2 0.02   0.1 
Hyper-CVAD Cycle 4 0.3 0.02   0.05 
4 months post HSCT 0.02  0.04   <0.02 <0.02 
 
BM, bone marrow; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual 
disease; PB, peripheral blood; Hyper-CVAD, hyperfractionated therapy of cyclophosphamide, 
vincristine, doxorubicin and dexamethasone. 
 

